Exclusive Journals Coverage articles provide quick insight and additional author perspectives on select studies recently published in Journal of Clinical Oncology and Journal of Oncology Practice.
Jul 14, 2014
To explain the rise in oropharyngeal squamous cell carcinoma (OPSCC), researchers turned to another historic trend—the increase, since the late 1970s, in the number of people carrying human papillomavirus (HPV), an infection known to cause OPSCC . . .
Jul 07, 2014
“We wanted to determine if the association is also seen in two relatively common conditions in elderly American men—depression and prostate cancer—in terms of the effects on treatment choices as well as survival,” said Jim Hu, MD, MPH, a co-author on the study . . .
Jun 30, 2014
The study showed it was possible to successfully link a statewide registry that collects data on surgical quality with the tumor registries of 10 hospitals. The database created from the linkage will serve as a platform for a quality assessment program for rectal cancer surgery.
Jun 23, 2014
The study found that among patients with non-metastatic colorectal cancer, those who consumed more calcium and milk after their diagnosis had a lower rate of death from all causes. These same benefits were not seen in those who consumed more vitamin D . . .
Jun 16, 2014
By Jo Cavallo
Jun 02, 2014
“For one patient, a 2 or 3% absolute benefit in terms of recurrence rate may be important enough that she would choose to take chemotherapy with all of its various side effects. And for another patient, that same exact amount of benefit is not enough to warrant taking chemotherapy."
May 31, 2014
Watch an exclusive video of Dr. Hudis delivering his Presidential Address at the 50th Meeting of the American Society of Clinical Oncology. The complete transcript is also included.
May 27, 2014
The findings? At the four- to six-month point, women who had received chemotherapy showed significantly decreased brain activity while completing the multitask exercise . . .
May 12, 2014
The study utilized the new technology to assess the clinical value of a panel that honed in on 42 potentially actionable genes among women at high risk for breast cancer who were BRCA negative. It is one of the first studies to focus specifically on patients. . .